The University of Kentucky Prevention Research Center’s (PRC)success with a cervical cancer prevention DVD, known as 1-2-3 Pap, has led to improved completion of the humanpapillomavirus (HPV) vaccine series.
The HPV vaccine can protect against two types of HPV that cause 70% of cervical cancer cases. While it is important for girls and women to receive all three doses of the vaccine, they do not always complete all three in the series. Completion requires girls to return to the clinic twice to receive the second dose at 2 months and the third dose after 6 months of the original dose. To help prevent cervical cancer, researchers at the University of Kentucky PRC developed and tested 1-2-3- Pap, an educational video that encourages young adult women in rural Appalachian Kentucky to complete the series.
Out of 178 young women who watched the video, 77 completed the series. Of those who did not watch the video (166 young women), 53 completed the series. Researchers found that participants who viewed the video were more than twice as likely (2.44 times) to complete the series than those who did not.
The University of Kentucky PRC is working with partners to adapt this model so it can be repeated in other underserved areas with high rates of cervical cancer. The program was adapted and adopted by 18 local health departments in Kentucky, reaching a total of 41 counties. This successful distribution led to requests from North Carolina and West Virginia for assistance in developing versions tailored to their states. The West Virginia version was widely distributed by the West Virginia Immunization Network. An article about the outreach for and implementation of the 1-2-3 Pap video program will be published in the August 2015 issue of the American Journal of Preventive Medicine.
The 1-2-3 Pap video is the first communication study promoting completion of the three-dose HPV vaccine series in communities. See the three different versions of the DVD:
1. Kentucky
Learn more about the Prevention Research Centers Program and cervical cancer.
No hay comentarios:
Publicar un comentario